The Quantellect read.As of Nov 19, 2026, 4 active firms cover Black Diamond Therapeutics Inc: 3 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $8.00 to $14.00, a moderate spread. The average target of $11.00 sits 675% above the current $1.42. The rating mix has stayed broadly stable, with Buy-side ratings easing from 5 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-0.99 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy375%
Neutral125%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$11.00
+674.6% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.42 current
Highest Target$14.00
Average Target$11.00
Lowest Target$8.00
Detailed analyst forecasts for BDTX
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 3 of 4 active firms rate BDTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BDTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.36 – $-0.20 · 4 analysts · +55% YoY
Next period, 4 analysts expect Black Diamond Therapeutics Inc to earn $-0.25 a share (range $-0.36 – $-0.20), versus $-0.16 a year earlier. Full-year consensus is $-0.69, growing to $-0.99 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Black Diamond Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BDTX.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$10.00+604.2% to target
Overall win rate
42%
+ Follow
#2
Robert Driscoll
Wedbush · Rank #490
Buy
$14.00+885.9% to target
Overall win rate
32%
+ Follow
#3
LP
Laura Prendergast
Stifel
Buy
$8.00+463.4% to target
Coverage
—
+ Follow
#4
Sean McCutcheon
Raymond James
Buy
$11.00+674.6% to target
Coverage
—
+ Follow
#5
Kelsey Goodwin
Piper Sandler
Buy
$8.00+463.4% to target
Coverage
—
+ Follow
BDTX stock forecast FAQ
What is BDTX's average 12-month price target?+
The 3 active firms with a live target average $11.00 for Black Diamond Therapeutics Inc over the next 12 months, ranging from a $14.00 high to a $8.00 low, as of Nov 19, 2026.
Is BDTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BDTX?+
The Street-high target is $14.00 (Wedbush), and the Street-low is $8.00 (Piper Sandler). The average of all 3 active-firm targets is $11.00.
How many active Wall Street firms cover BDTX?+
4 active firms have a recognized rating on Black Diamond Therapeutics Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BDTX?+
Among analysts who currently cover BDTX, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #215). Their current call is Buy with a $10.00 target.
What is Black Diamond Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.36 – $-0.20) across 4 analysts. Full-year EPS is projected at $-0.69, rising to $-0.99 the following year.
How much revenue is Black Diamond Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading BDTX lately?+
As of Nov 19, 2026, 3 of 4 active firms rate BDTX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BDTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.